证券代码：000525 证券简称：ST 红太阳 公告编号：2024－039 南京红太阳股份有限公司 第九届董事会第十五次会议决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确和完整，没有虚假记载、 误导性陈述或重大遗漏。 南京红太阳股份有限公司（以下简称"公司"）第九届董事会第十 五次会议于 2024 年 5 月 9 日在南京市高淳经济开发区古檀大道 18 号 公司会议室以现场与通讯相结合的方式召开。本次会议通知于 2024 年 5 月 6 日以书面、邮件或通讯等方式发出。本次会议应参加表决董 事 9 名，实际参加表决董事 9 名。会议由公司董事长杨秀先生主持。 公司监事及高级管理人员列席本次会议。会议的召集和召开符合《公 司法》和《公司章程》等有关规定。会议审议并通过了以下议案： 2024 年 5 月 10 日 1 经公司独立董事专门会议审议，一致同意该议案并同意将该议案 提交公司董事会审议；因张兰平先生为公司现任副总经理，根据《深 圳证券交易所股票上市规则》相关规定，张兰平先生系公司关联自然 人，本次共同投资事项构成关联交易。 具体内容详见同日公司在巨潮资讯网披露的《关于公司全资孙公 司拟投资设 ...

南京红太阳股份有限公司 关于公司预重整事项的进展公告 证券代码：000525 证券简称：ST 红太阳 公告编号：2024-037 本公司及董事会全体成员保证信息披露的内容真实、准确和完整，没有虚假记载、 误导性陈述或重大遗漏。 2022 年 9 月 16 日，南京红太阳股份有限公司（以下简称"公司"） 收到南京市中级人民法院（以下简称"南京中院"）送达的（2022） 苏 01 破申 62 号《决定书》，决定对公司启动预重整程序。根据深圳 证券交易所《股票上市规则》、《上市公司自律监管指引第 14 号— 破产重整等事项》的相关规定，公司就预重整事项相关进展情况公告 如下： 一、预重整事项的进展情况 公司于 2022 年 9 月 20 日披露的《关于公司被债权人申请重整的 提示性公告》，公司收到南京中院送达的（2022）苏 01 破申 62 号《通 知书》及《重整申请书》，申请人南京太化化工有限公司以公司不能 清偿到期债务且明显缺乏清偿能力，但仍具备重整价值为由，向南京 中院申请对公司进行重整，并申请先行启动预重整程序。 公司于 2022 年 11 月 9 日披露了《关于法院决定对公司启动预重 整程序的公告》，公 ...

证券代码：000525 证券简称：ST 红太阳 公告编号：2024-036 南京红太阳股份有限公司 关于公司股票被实施其他风险警示相关事项的进展公告 本公司及董事会全体成员保证信息披露的内容真实、准确和完整，没有虚假记载、 误导性陈述或重大遗漏。 特别提示： 根据《深圳证券交易所股票上市规则》的相关规定，因南京红太阳股份有限 公司（以下简称"公司"）存在被控股股东南京第一农药集团有限公司及其关联方 （以下简称"南一农集团及其关联方"）非经营性资金占用的情形未消除，且公司 2020 年至 2023 年度均被出具否定意见的内部控制审计报告，自 2021 年 5 月 6 日起至今，公司股票被实施其他风险警示。 一、公司被实施其他风险警示相关事项的进展情况 （一）公司股票前期被实施其他风险警示的情形 1、截至公司 2020 年年报披露时，因公司存在被南一农集团及其 关联方非经营性资金占用的情形；同时，公司存在 2020 年度被出具 否定意见的内部控制审计报告。根据《深圳证券交易所股票上市规则》 的相关规定，公司股票自 2021 年 5 月 6 日开市起开始被实施其他风 险警示。具体详见 2021 年 4 月 30 日 ...

南京红太阳股份有限公司 关于全资子公司部分股权被司法拍卖的提示性公告 本公司及董事会全体成员保证信息披露的内容真实、准确和完整，没有虚假记载、 误导性陈述或重大遗漏。 证券代码：000525 证券简称：ST 红太阳 公告编号：2024-038 南京红太阳股份有限公司（以下简称"公司"）近日通过淘宝网司 法拍卖网络平台查询获悉，北京市第三中级人民法院（以下简称"北 京三中院"）将于2024年6月3日10时至2024年6月4日10时止（延时的 除外）在淘宝网司法拍卖网络平台上（网址：http://sf.taobao.com/010/03， 户名：北京市第三中级人民法院）对公司持有全资子公司安徽国星生 物化学有限公司（以下简称"安徽国星"）的20%股权进行公开拍卖。 现将具体情况公告如下： 一、拍卖的主要内容 1、拍卖标的：南京红太阳股份有限公司持有的安徽国星生物化 学有限公司20%股权。 本次拍卖为第一次拍卖，评估价：44,770万元，起拍价: 31,339 万元，保证金：6,000万元，增价幅度：150万。 2、拍卖时间：2024年6月3日10时至2024年6月4日10时止（延时 的除外）。 二、被拍卖标的公司 ...

Financial Performance - The company's operating revenue for Q1 2024 was ¥845,695,858.31, representing a 13.15% increase compared to ¥747,388,776.20 in the same period last year[3]. - Net profit attributable to shareholders for Q1 2024 was ¥20,076,891.00, a significant increase of 77.41% from ¥11,316,969.11 in the previous year[3]. - Total operating revenue for Q1 2024 was CNY 845,695,858.31, an increase of 13.14% compared to CNY 747,388,776.20 in the same period last year[14]. - Net profit for Q1 2024 reached CNY 19,034,959.53, compared to CNY 7,697,450.67 in Q1 2023, representing a growth of 147.5%[15]. - Operating profit for Q1 2024 was CNY 30,641,178.67, significantly up from CNY 7,398,957.98 in the same period last year[15]. - The company reported a total profit of CNY 28,071,417.98 for Q1 2024, compared to CNY 7,215,593.49 in Q1 2023, marking an increase of 288.5%[15]. Cash Flow and Assets - The net cash flow from operating activities decreased by 45.53% to ¥36,722,129.03, down from ¥67,421,620.44 in the same period last year[3]. - The company's cash and cash equivalents decreased to CNY 291,792,379.29 from CNY 313,622,798.02, reflecting a decline of 6.67%[11]. - Cash flow from operating activities generated CNY 36,722,129.03, down from CNY 67,421,620.44 in Q1 2023[19]. - Cash and cash equivalents at the end of Q1 2024 were CNY 47,558,807.72, a decrease from CNY 144,913,759.77 at the end of Q1 2023[19]. Assets and Liabilities - The company's total assets at the end of Q1 2024 were ¥9,843,276,617.95, a slight decrease of 0.20% from ¥9,862,963,239.83 at the end of the previous year[3]. - Total assets decreased slightly to CNY 9,843,276,617.95 from CNY 9,862,963,239.83, a decrease of 0.2%[13]. - Total liabilities decreased to CNY 8,809,584,160.70 from CNY 8,865,442,844.32, a reduction of 0.63%[13]. - The company's equity attributable to shareholders increased to CNY 909,107,817.92 from CNY 878,819,135.76, an increase of 3.4%[13]. - The company reported a decrease in short-term borrowings to CNY 3,258,213,003.63 from CNY 3,365,854,459.77, a decline of 3.3%[13]. Inventory and Receivables - The company reported a significant increase in inventory, which rose by 37.16% to ¥1,019,849,744.19 compared to ¥743,531,278.03 at the beginning of the period[6]. - Inventory increased significantly to CNY 1,019,849,744.19 from CNY 743,531,278.03, marking an increase of 37.4%[12]. - Accounts receivable decreased to CNY 628,064,937.09 from CNY 844,562,577.75, a reduction of 25.6%[12]. Shareholder Information - The number of ordinary shareholders at the end of the reporting period was 23,875[8]. - The largest shareholder, Nanjing First Pesticide Group Co., Ltd., holds a 31.50% stake in the company[8]. Government Support and Expenses - The company received government subsidies amounting to ¥10,879,267.46 during the reporting period[4]. - Research and development expenses increased slightly to CNY 46,222,881.24 from CNY 45,162,420.36, indicating a focus on innovation[15]. Operating Costs - Total operating costs for Q1 2024 were CNY 846,335,212.37, an increase of 12.2% from CNY 754,331,508.01 in Q1 2023[15]. Market and Product Development - The company has no new product launches or technological developments reported in this quarter[12]. - There are no significant market expansion or acquisition strategies mentioned in the report[12].

Financial Performance - The company reported a significant financial performance with a total revenue of RMB 1.2 billion, representing a year-on-year increase of 15%[17]. - The company's operating revenue for 2023 was ¥3,232,236,356.18, a decrease of 49.81% compared to ¥6,439,912,658.86 in 2022[22]. - The net profit attributable to shareholders was -¥389,116,496.12, representing a decline of 153.13% from ¥732,297,405.94 in the previous year[22]. - The total revenue for the year 2022 was 10,549 million RMB, indicating a stable performance[143]. - The total revenue for the year 2023 was reported at 1.2 billion RMB, representing a year-on-year increase of 15%[152]. User Growth and Market Expansion - User data indicates a growth in customer base, with an increase of 20% in active users compared to the previous year[17]. - User data indicates a growing customer base in South America, with significant sales recorded in countries like Argentina and Paraguay[67]. - The company is expanding its market presence, targeting a 25% increase in distribution channels across rural areas[17]. - The company plans to expand its market presence in Southeast Asia, targeting a 15% market share by 2025[152]. - The company is actively pursuing international markets, with registrations in countries like Australia, Mexico, and Nigeria for its products[65]. Product Development and Innovation - New product development includes the launch of three innovative pesticide formulations, expected to contribute an additional RMB 200 million in revenue[17]. - The company has a strong emphasis on R&D, with dedicated teams for new product development and feasibility studies[51]. - The company is focusing on the development of green pesticides in response to increasing environmental regulations and market demand for eco-friendly products[46]. - The company is actively developing new products and technologies, with a notable emphasis on innovative pesticide formulations to enhance market competitiveness[67]. - The company has established a comprehensive technological innovation system for the green pesticide industry, with 4 national R&D platforms and 8 provincial R&D platforms, employing over 639 technical personnel and holding more than 600 patents, of which over 90% are invention patents[73]. Financial Guidance and Strategic Planning - The company has provided a positive outlook for the next fiscal year, projecting a revenue growth of 10% to 12%[17]. - Future guidance suggests a targeted revenue growth of approximately 10% for the next fiscal year[143]. - The company has set a revenue guidance for 2024 at 1.5 billion RMB, projecting a growth rate of 25%[152]. - The company aims to create six national product champions and two unicorn enterprises by the end of the year, focusing on six major product series including new pyridine, paraquat, and biological enzyme engineering technology[125]. Acquisitions and Partnerships - A strategic acquisition of a local competitor is in progress, which is anticipated to enhance market share by 5%[17]. - A strategic acquisition of a local competitor was completed, expected to enhance market competitiveness and increase revenue by 5%[152]. - Strategic acquisitions and partnerships are being explored to bolster market expansion and product offerings in key regions[68]. Internal Control and Governance - The company is focusing on improving its internal governance and control management capabilities, particularly regarding related party transactions and historical financial issues[160]. - The company has established a governance structure that includes a board of directors and supervisory board to ensure effective decision-making and risk management[134][135]. - The company has revised ten internal governance documents, including the Articles of Association and the Rules of Procedure for Shareholders' Meetings, to enhance internal control systems[136]. - The company has established an independent financial department with a separate accounting system, ensuring independent financial decision-making[138]. Environmental Compliance and Sustainability - The company strictly adheres to various environmental protection standards, including GB 18484-2020 and DB 32/939-2020, ensuring compliance in waste management and emissions[188]. - The company is committed to legal disposal of solid waste, ensuring compliance with environmental regulations[188]. - The company has implemented third-party environmental monitoring and self-testing, confirming that air and wastewater emissions meet regulatory requirements[188]. - The company is actively engaged in environmental technology upgrades to promote clean production and energy conservation[188]. Challenges and Risks - The company is facing multiple risks including market competition, climate risks, and safety and environmental risks, which could impact its operations and profitability[126][127]. - The primary reasons for the company's losses in 2023 included abnormal weather in key markets, a drastic price drop in glyphosate products, and increased R&D expenses due to the successful development of four major industry chains[81]. - The company is actively monitoring the restructuring progress of its major shareholder to ensure the recovery of occupied funds and maintain operational stability[129]. Research and Development Investment - The company has allocated RMB 50 million for research and development in new agricultural technologies[17]. - Research and development expenses increased by 3.34% to ¥294,915,675.24, reflecting ongoing investment in innovation[101]. - The company reported a significant investment loss of ¥50,025,877.93 from the disposal of trading financial assets, which accounted for 9.32% of total profit[106]. Operational Efficiency - The company has implemented new operational strategies aimed at improving supply chain efficiency, projected to reduce costs by 8%[152]. - The company achieved significant success in creating a new digital operation management model, enhancing capabilities in online operations, supply chain management, and data analysis[88]. - The company is focusing on optimizing its product structure and expanding into other international markets to mitigate the impact of extreme weather on product demand[127].

Financial Performance Expectations - The company expects a net loss attributable to shareholders of between 280 million and 360 million RMB for the fiscal year 2023, a decline of 138.24% to 149.16% compared to a profit of 732.30 million RMB in 2022 [2]. - The net profit after deducting non-recurring gains and losses is projected to be a loss of 550 million to 690 million RMB, down 173.55% to 192.27% from a profit of 747.80 million RMB in the previous year [3]. - Basic earnings per share are expected to be a loss of 0.48 to 0.62 RMB, compared to earnings of 1.26 RMB per share in 2022 [3]. - Operating revenue is forecasted to be between 3.3 billion and 3.6 billion RMB, significantly lower than the 6.44 billion RMB reported in 2022 [2]. Audit and Forecast Adjustments - The company revised its previous profit forecast due to insufficient impairment provisions and accounting treatment discrepancies identified during the annual audit process [5]. - The company has communicated with its auditing firm regarding the performance forecast adjustments, and there are no significant disagreements on the accounting treatment [4]. - The final financial data for 2023 will be subject to the audit results from the accounting firm [6]. Investor Communication and Risk Management - The company has expressed apologies for any inconvenience caused to investors due to the performance forecast revision [6]. - The company is currently under other risk warnings and may continue to face such risks following the disclosure of the 2023 annual report [7]. - The company aims to enhance the accuracy of performance forecasts through improved training for relevant personnel and adherence to regulations [6].

证券代码：000525 证券简称：ST 红太阳 公告编号：2024－019 具体内容详见同日公司在巨潮资讯网披露的《关于新增与 14 户 债权人签署债权豁免、债权抵偿相关协议暨关联交易的议案》。 1 特此公告。 南京红太阳股份有限公司 第九届监事会第十次会议决议公告 监事会全体成员保证公告的内容真实、准确、完整，没有虚假记载、误导性陈述或 重大遗漏。 南京红太阳股份有限公司（以下简称"公司"）第九届监事会第十 次会议于 2024 年 4 月 25 日在南京市高淳经济开发区古檀大道 18 号 公司会议室以现场与通讯相结合的方式召开。本次会议通知于 2024 年 4 月 22 日以书面、邮件或通讯等方式发出。本次会议应参加表决 监事 5 名，实际参加表决监事 5 名。会议由公司监事会主席杨晓生先 生主持。会议的召集和召开符合《公司法》和《公司章程》等有关规 定。会议审议并通过了以下议案： 一、审议并通过了《关于新增与 14 户债权人签署债权豁免、债 权抵偿相关协议暨关联交易的议案》。 监事会意见：自发生债务危机以来，公司积极推进司法重整，通 过一揽子方案推动化解债务风险和解决控股股东及其关联方资金占 用问题。公司 ...

证券代码：000525 证券简称：ST 红太阳 公告编号：2024-020 南京红太阳股份有限公司 1、近日，南京红太阳股份有限公司（以下简称"红太阳股份"或"公司"）收到公 司相关部门送达的书面协议文件，获悉：本次公司、公司子公司新增与 14 户债权人 签署了债权豁免、债权抵偿相关协议，相关债权人自愿豁免其对公司、公司子公司 的部分债权，或以其部分债权帮助南京第一农药集团有限公司（以下简称"南一农集 团"）、红太阳集团有限公司（以下简称"红太阳集团"）等额抵偿对公司的资金占用 金额，相关豁免或代偿债权不再向公司、公司子公司追偿。 2、本次签署债权豁免以及债权代偿协议事项经公司独立董事专门会议审议，一 致同意该事项并同意将该事项提交公司董事会审议；该事项构成关联交易，已经公 司第九届董事会第十三会议、第九届监事会第十次会议审议通过，关联董事回避表 决，非关联董事一致同意。该事项尚需提交股东大会审议（具体会议时间另行通知）。 本次关联交易不构成重大资产重组。 请广大投资者理性投资并注意投资风险。 一、协议签订背景及概述 关于新增与 14 户债权人签署债权豁免、债权抵偿相关协议暨关联交易的公告 本公司及董事会全体 ...

南京红太阳股份有限公司 独立董事 2024 年第二次专门会议决议 独立董事：吴学民、冯丽艳、严震 2024 年 4 月 24 日 经独立董事专门会议审议，我们一致认为：公司本次与债权人签 署债权豁免、债权抵偿相关协议，为公司解决债务问题有积极推动作 用，有利于改善公司资产负债结构；对公司加快进入司法重整程序有 积极的影响；对解决南一农集团、红太阳集团对公司的资金占用问题 有实质性的促进作用，符合公司和全体股东的利益，不存在损害公司 及股东尤其是中小股东利益的情形。 综上，我们一致同意该议案，并同意将该议案提交公司第九届董 事会第十三次会议审议，公司关联董事需回避表决。 表决结果：同意 3 票，反对 0 票，弃权 0 票。 南京红太阳股份有限公司（以下简称"公司"）独立董事2024年第 二次专门会议于2024年4月24日以现场与通讯相结合方式召开，本次 会议已于2024年4月22日以通讯方式通知全体独立董事。本次会议应 出席独立董事3人，实际出席独立董事3人，经过半数独立董事推举， 独立董事冯丽艳女士召集并主持本次会议。本次会议的召开和表决程 序符合《上市公司独立董事管理办法》、《公司独立董事专门会议议事 规则 ...